Introduction
TNBC, tumor, death, breast cancer
TRIPLE-NEGATIVE BREAST CANCER, TUMOR, BREAST CANCER, DISEASE, DYSFUNCTION
Triple-negative breast cancer (TNBC) is a subtype that accounts for approximately 15–20% of all breast cancer diagnoses. Clinically defined as lacking ER, PR, and HER2 expression, TNBC is characterized by an aggressive natural history and worse survival outcomes compared with other breast cancer subtypes [Neoadjuvant chemotherapy (NACT) remains the mainstay of early-stage and locally advanced disease treatment, and pathological complete response (pCR) as a surrogate endpoint is well-established in TNBC [Over the past years, there has been considerable interest in using platinum salts in treating TNBC because homologous recombination DNA repair dysfunction sensitizes tumor cells to these agents and induces cell death [Therefore, we conducted a phase II randomized clinical trial to evaluate if adding carboplatin to standard NACT could increase the pCR rate in patients with known BRCA status presenting with early-stage and locally advanced TNBC in Brazil.